Swedish biotech company ready for phase III
Before the end of the year, Stockholm-based Pledpharma will initiate clinical trials with the company’s main candidate Pledox in 500 patients from Europe and the US.
BY MIKKEL AABENHUS HEMMINGSEN
The development of the Swedish biotech company Pledpharma’s candidate drug Pledox is about to enter the pivotal stage.
Allerede abonnent?Log ind her
Læs hele artiklen
Få adgang i 14 dage for 0 kr. Det kræver intet kreditkort, og du vil ikke overgå til et betalt abonnement efterfølgende.
